Dr. Costantin has a solid and highly impressive track record in customer relation management, in-depth knowledge of ion channel drug discovery, and over 12 years of technical expertise with automated electrophysiology platforms.
With the successful roll-out and rapidly growing installed base of the SyncroPatch 384/768PE, an advanced robotic ion channel high throughput screening platform, Nanion has expanded the US-team to increasingly focus on sales and customer support in this business segment. James Costantin has extensive experience in automated patch clamp (APC)-based ion channel drug discovery and has been instrumental in the development, deployment, and usage of automated patch clamp platforms.
Rodolfo Haedo, VP Nanion Technologies Inc., says:
"With the booming interest in the SyncroPatch 384/768PE and APC-based ion channel drug discovery from both pharma and academic laboratories, we anticipate another strong year for the SyncroPatch 384/768PE and we’re thrilled to have James Costantin on board. He is known for his dedication and customer focus, as well as for his profound knowledge and understanding of APC in drug discovery HTS applications. James is the perfect match for Nanion and with him on board, we’ll also strengthen our presence on the US-West coast."
Dr. James Costantin continues:
"Nanion is one of the few companies in this business showing exceptional stability and continuous dynamic company growth, they consistently have had a strong focus on technical product development and product management. I find the SyncroPatch 384/768PE platform to be extremely impressive due to its great technical capabilities, and with the new modular concept of integration into pre-existing robotic platforms, it is the only APC instrument that can rapidly be incorporated into fully automated HTS workflows. Nanion's HTS-system paves the way for a new standard in APC-based ion channel screening and I'm quite pleased to join such a dedicated and dynamic team to serve our expanding customer base."
With the successful roll-out and rapidly growing installed base of the SyncroPatch 384/768PE, an advanced robotic ion channel high throughput screening platform, Nanion has expanded the US-team to increasingly focus on sales and customer support in this business segment. James Costantin has extensive experience in automated patch clamp (APC)-based ion channel drug discovery and has been instrumental in the development, deployment, and usage of automated patch clamp platforms.
Rodolfo Haedo, VP Nanion Technologies Inc., says:
"With the booming interest in the SyncroPatch 384/768PE and APC-based ion channel drug discovery from both pharma and academic laboratories, we anticipate another strong year for the SyncroPatch 384/768PE and we’re thrilled to have James Costantin on board. He is known for his dedication and customer focus, as well as for his profound knowledge and understanding of APC in drug discovery HTS applications. James is the perfect match for Nanion and with him on board, we’ll also strengthen our presence on the US-West coast."
Dr. James Costantin continues:
"Nanion is one of the few companies in this business showing exceptional stability and continuous dynamic company growth, they consistently have had a strong focus on technical product development and product management. I find the SyncroPatch 384/768PE platform to be extremely impressive due to its great technical capabilities, and with the new modular concept of integration into pre-existing robotic platforms, it is the only APC instrument that can rapidly be incorporated into fully automated HTS workflows. Nanion's HTS-system paves the way for a new standard in APC-based ion channel screening and I'm quite pleased to join such a dedicated and dynamic team to serve our expanding customer base."
